Assessment of Heavy Metal Concentration in Soil Impacted Mining-Overburden in Enyigba, Abakaliki, Ebonyi State, Nigeria

This study assessed the concentration of selected heavy metals (Lead and Zinc) from surrounding soil of Royal Salt mining company, Enyigba in Abakaliki LGA, Ebonyi State. Soil samples were collected from nine (9) different locations at depths of 0-15 and 15-30cm. Two (2) samples were collected from each of the nine locations, making it total of eighteen (18) samples. Soil analysis carried out were particle size distribution, pH, available Phosphorus, total Nitrogen, Organic Carbon, organic matter, Calcium, Magnesium, Potassium, Sodium, exchangeable acidity, Aluminium, effective cation exchange capacity, base saturation and two selected heavy metals, Lead (Pb) and Zinc (Zn). Results shows that heavy metals were highest in soil around the disposal site of mine waste. The highest value of Pb and Zn was recorded on tailing down (TD) 14.82 and 25.33mg/kg at 0-15cm depth, 7.22 and 18.93mg/kg at 15-30cm depth respectively. The accumulation of Pb and Zn at the mining site (TD) may be due to mining activities, civil, industrial/anthropogenic activities going on around the site. This study recommends regular monitoring of heavy metal  concentration in soil within the mining site and their disposal site in order to conform to international standards set by the WHO. Keywords: Abakaliki, Enyigba, Lead, Royal Salt Limited, Zin

Women Education and Sustainable Economic Development in Nigeria

The paper focuses on the role of women education in ensuring sustainable economic development in Nigeria. The paper relied on the use of secondary source of data collection for data analysis. As such, qualitative method of data analysis was employed. The concept of womanhood was defined as well as the meaning of women education. The meaning of sustainable development was also highlighted. The factors that inhibit the education of women such as cultural beliefs, low self esteem among women and inadequate infrastructures were also highlighted. The role of women in ensuring sustainable economic development such as quality leadership, increase in GDP and reduction in dependency rate in the country were also identified. Ways of improving the education of women in the country such as provision of infrastructures, proper legislation and provision of education grant to female students were similarly suggested. It was therefore recommended that for women education to contribute to sustainable economic development in the country the government must make proper legislation to support women education and the various educational stakeholders must contribute immensely to the success of women education in the country. Key words: Women Education, Sustainable Development, Quality Leadership, Insecurity and Gender Equalit

The Role of Universities in Human Capital Development: Implications for National Transformation

This study investigated the role of Universities in human capital development in Cross River State and its implication for national transformation. Ex-post facto design was adopted in the study. Two research questions and hypotheses respectively were raised to guide the study. A sample of 227 lecturers were drawn from a population of 1,517 lecturers from the two universities. The Role of Universities in Human Capital Development for National Transformation Questionnaire (TRUIHCDFNTQ) was used to generate data. The data were analyzed using Pearson’s Product Moment Correlation Coefficient. From the results, it was concluded that opportunities for attending retraining programmes and conferences/workshops had significant relationship with lecturers’ transformation in terms of their teaching effectiveness and subsequent national transformation. Based on the findings it was recommended that; Government should provide funds to the universities to sponsor lecturers to attend retraining programmes. Keywords: The Role of Universities, Human Capital Development, National Transformation

Assessment of Heavy Metal Concentration in Soil Impacted Mining-Overburden in Enyigba, Abakaliki, Ebonyi State, Nigeria

This study assessed the concentration of selected heavy metals (Lead and Zinc) from surrounding soil of Royal Salt mining company, Enyigba in Abakaliki LGA, Ebonyi State. Soil samples were collected from nine (9) different locations at depths of 0-15 and 15-30cm. Two (2) samples were collected from each of the nine locations, making it total of eighteen (18) samples. Soil analysis carried out were particle size distribution, pH, available Phosphorus, total Nitrogen, Organic Carbon, organic matter, Calcium, Magnesium, Potassium, Sodium, exchangeable acidity, Aluminium, effective cation exchange capacity, base saturation and two selected heavy metals, Lead (Pb) and Zinc (Zn). Results shows that heavy metals were highest in soil around the disposal site of mine waste. The highest value of Pb and Zn was recorded on tailing down (TD) 14.82 and 25.33mg/kg at 0-15cm depth, 7.22 and 18.93mg/kg at 15-30cm depth respectively. The accumulation of Pb and Zn at the mining site (TD) may be due to mining activities, civil, industrial/anthropogenic activities going on around the site. This study recommends regular monitoring of heavy metal concentration in soil within the mining site and their disposal site in order to conform to international standards set by the WHO

Toxicity study of diethyl phthalate on Clarias gariepinus fingerlings

Diethyl Phthalate (DEP) is used as a plasticizer, a detergent base, in aerosol sprays, as a perfume binder and after shave lotion. It is known to be a contaminant of fresh water and marine ecosystem. Therefore, a study was designed to determine the acute toxicity effects of DEP on a fresh water fish, Clarias gariepinus fingerlings. The fish was treated with 50, 75, 100 and 150 μg/l. DEP was dissolved in distilled water to determine the LC50. There was 100% mortality observed in 150 μg/l. The LC50 of DEP was estimated at log toxicant concentration as 2.217, 2.734, 3.435 and 3.931 μg/l at 24, 48, 72, 96 h and 1.871μg/l for the total death. This shows that the impacts are dose and time dependent with respect to marked reduction in mortality rate. At sub-lethal concentrations of the test substance at 30, 40, 60 and 80 μg/l in a renewal bioassay system, the water and the test compound were changed intermittently. One group was maintained as a control in dechlorinated water. There was significant difference (P < 0.05) in brain and muscle AchE activity compared to the control. The liver ACP activity was statistically significant (P < 0.05) at day 15 while the muscle ACP in other treatment groups showed no significant difference (P > 0.05). Liver AST showed no significance in all treated groups (P > 0.05) and liver ALT activity was statistically significant (P < 0.05) at day 30 only. The haematological parameters (HB, PCV, RBC and WBC) carried out showed that haemoglobin and erythrocyte levels estimated in all treatment groups to the duration of exposure showed no significant difference (P > 0.05) compared to the control. The park cell volume showed a significant difference (P < 0.05) at day 30 only. The leucocyte count throughout the exposure period showed that the mean values are statistically significant (P < 0.05) at day 15 only compared to the control. The mean cell volume (MCV) showed a significant difference at day 15 (P < 0.05) whereas mean cell haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC) showed no significant difference (P > 0.05) throughout the exposure period. No significant difference was seen between the lymphocytes and the neutrophils. In day 0 and 15 only, the monocytes and the lymphocytes showed a significant difference (P < 0.05). The gill damages indicated toxicity of DEP with raised lamella, oedema of the lamella epithelia, loss of lamellar epithelium, mild oedema and raising of the filament. The liver damage showed focal necrosis and vacuolization, hepatocyte degeneration in the liver. These alterations may have long term effects on that that are continuously exposed to DEP in the aquatic environment.Keywords: Diethyl phthalate, Clarias gariepinus, acute toxicity, sublethal toxicity, heamatology, biochemical, histopathology, environment

Measuring oxygen access: lessons from health facility assessments in Lagos, Nigeria

The COVID-19 pandemic has highlighted global oxygen system deficiencies and revealed gaps in how we understand and measure ‘oxygen access’. We present a case study on oxygen access from 58 health facilities in Lagos state, Nigeria. We found large differences in oxygen access between facilities (primary vs secondary, government vs private) and describe three key domains to consider when measuring oxygen access: availability, cost, use. Of 58 facilities surveyed, 8 (14%) of facilities had a functional pulse oximeter. Oximeters (N=27) were typically located in outpatient clinics (12/27, 44%), paediatric ward (6/27, 22%) or operating theatre (4/27, 15%). 34/58 (59%) facilities had a functional source of oxygen available on the day of inspection, of which 31 (91%) facilities had it available in a single ward area, typically the operating theatre or maternity ward. Oxygen services were free to patients at primary health centres, when available, but expensive in hospitals and private facilities, with the median cost for 2 days oxygen 13 000 (US$36) and 27 500 (US$77) Naira, respectively. We obtained limited data on the cost of oxygen services to facilities. Pulse oximetry use was low in secondary care facilities (32%, 21/65 patients had SpO2 documented) and negligible in private facilities (2%, 3/177) and primary health centres (<1%, 2/608). We were unable to determine the proportion of hypoxaemic patients who received oxygen therapy with available data. However, triangulation of existing data suggested that no facilities were equipped to meet minimum oxygen demands. We highlight the importance of a multifaceted approach to measuring oxygen access that assesses access at the point-of-care and ideally at the patient-level. We propose standard metrics to report oxygen access and describe how these can be integrated into routine health information systems and existing health facility assessment tools

Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) are used in many low-income countries but their impact on the incidence of pneumonia is unclear. The Gambia introduced PCV7 in August, 2009, and PCV13 in May, 2011. We aimed to measure the impact of the introduction of these vaccines on pneumonia incidence. METHODS: We did population-based surveillance and case-control studies. The primary endpoint was WHO-defined radiological pneumonia with pulmonary consolidation. Population-based surveillance was for suspected pneumonia in children aged 2-59 months (minimum age 3 months in the case-control study) between May 12, 2008, and Dec 31, 2015. Surveillance for the impact study was limited to the Basse Health and Demographic Surveillance System (BHDSS), whereas surveillance for the case-control study included both the BHDSS and Fuladu West Health and Demographic Surveillance System. Nurses screened all outpatients and inpatients at all health facilities in the surveillance area using standardised criteria for referral to clinicians in Basse and Bansang. These clinicians recorded clinical findings and applied standardised criteria to identify patients with suspected pneumonia. We compared the incidence of pneumonia during the baseline period (May 12, 2008, to May 11, 2010) and the PCV13 period (Jan 1, 2014, to Dec 31, 2015). We also investigated the effectiveness of PCV13 using case-control methods between Sept 12, 2011, and Sept 31, 2014. Controls were aged 90 days or older, and were eligible to have received at least one dose of PCV13; cases had the same eligibility criteria with the addition of having WHO-defined radiological pneumonia. FINDINGS: We investigated 18 833 children with clinical pneumonia and identified 2156 cases of radiological pneumonia. Among children aged 2-11 months, the incidence of radiological pneumonia fell from 21·0 cases per 1000 person-years in the baseline period to 16·2 cases per 1000 person-years (23% decline, 95% CI 7-36) in 2014-15. In the 12-23 month age group, radiological pneumonia decreased from 15·3 to 10·9 cases per 1000 person-years (29% decline, 12-42). In children aged 2-4 years, incidence fell from 5·2 to 4·1 cases per 1000 person-years (22% decline, 1-39). Incidence of all clinical pneumonia increased by 4% (-1 to 8), but hospitalised cases declined by 8% (3-13). Pneumococcal pneumonia declined from 2·9 to 1·2 cases per 1000 person-years (58% decline, 22-77) in children aged 2-11 months and from 2·6 to 0·7 cases per 1000 person-years (75% decline, 47-88) in children aged 12-23 months. Hypoxic pneumonia fell from 13·1 to 5·7 cases per 1000 person-years (57% decline, 42-67) in children aged 2-11 months and from 6·8 to 1·9 cases per 1000 person-years (72% decline, 58-82) in children aged 12-23 months. In the case-control study, the best estimate of the effectiveness of three doses of PCV13 against radiological pneumonia was an adjusted odds ratio of 0·57 (0·30-1·08) in children aged 3-11 months and vaccine effectiveness increased with greater numbers of doses (p=0·026). The analysis in children aged 12 months and older was underpowered because there were few unvaccinated cases and controls. INTERPRETATION: The introduction of PCV in The Gambia was associated with a moderate impact on the incidence of radiological pneumonia, a small reduction in cases of hospitalised pneumonia, and substantial reductions of pneumococcal and hypoxic pneumonia in young children. Low-income countries that introduce PCV13 with reasonable coverage can expect modest reductions in hospitalised cases of pneumonia and a marked impact on the incidence of severe childhood pneumonia. FUNDING: GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan, Bill & Melinda Gates Foundation, and UK Medical Research Council

Pulse oximetry and oxygen services for the care of children with pneumonia attending frontline health facilities in Lagos, Nigeria (INSPIRING-Lagos): study protocol for a mixed-methods evaluation

INTRODUCTION: The aim of this evaluation is to understand whether introducing stabilisation rooms equipped with pulse oximetry and oxygen systems to frontline health facilities in Ikorodu, Lagos State, alongside healthcare worker (HCW) training improves the quality of care for children with pneumonia aged 0-59 months. We will explore to what extent, how, for whom and in what contexts the intervention works. METHODS AND ANALYSIS: Quasi-experimental time-series impact evaluation with embedded mixed-methods process and economic evaluation. SETTING: seven government primary care facilities, seven private health facilities, two government secondary care facilities. TARGET POPULATION: children aged 0-59 months with clinically diagnosed pneumonia and/or suspected or confirmed COVID-19. INTERVENTION: 'stabilisation rooms' within participating primary care facilities in Ikorodu local government area, designed to allow for short-term oxygen delivery for children with hypoxaemia prior to transfer to hospital, alongside HCW training on integrated management of childhood illness, pulse oximetry and oxygen therapy, immunisation and nutrition. Secondary facilities will also receive training and equipment for oxygen and pulse oximetry to ensure minimum standard of care is available for referred children. PRIMARY OUTCOME: correct management of hypoxaemic pneumonia including administration of oxygen therapy, referral and presentation to hospital. SECONDARY OUTCOME: 14-day pneumonia case fatality rate. Evaluation period: August 2020 to September 2022. ETHICS AND DISSEMINATION: Ethical approval from University of Ibadan, Lagos State and University College London. Ongoing engagement with government and other key stakeholders during the project. Local dissemination events will be held with the State Ministry of Health at the end of the project (December 2022). We will publish the main impact results, process evaluation and economic evaluation results as open-access academic publications in international journals. TRIAL REGISTRATION NUMBER: ACTRN12621001071819; Registered on the Australian and New Zealand Clinical Trials Registry

Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.

BACKGROUND: Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011. METHODS: We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008-May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013-Dec 31, 2014), adjusting for changes in case ascertainment over time. FINDINGS: We investigated 14 650 patients, in whom we identified 320 cases of invasive pneumococcal disease. Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 30-71) in the 2-23 months age group, from 253 to 113 per 100 000 population. This decrease was due to an 82% (95% CI 64-91) reduction in serotypes covered by the PCV13 vaccine. In the 2-4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25-75), from 113 to 49 cases per 100 000, with a 68% (95% CI 39-83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children aged 2-59 months increased by 47% (-21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The incidence of non-pneumococcal bacteraemia varied little over time. INTERPRETATION: The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2-59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2-4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease. FUNDING: GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & Melinda Gates Foundation, and the UK Medical Research Council

Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.

BACKGROUND: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV7) in August 2009, followed by PCV13 in May, 2011, using a schedule of three primary doses without a booster dose or catch-up immunisation. We aimed to assess the long-term impact of PCV on disease incidence. METHODS: We did 10 years of population-based surveillance for invasive pneumococcal disease (IPD) and WHO defined radiological pneumonia with consolidation in rural Gambia. The surveillance population included all Basse Health and Demographic Surveillance System residents aged 2 months or older. Nurses screened all outpatients and inpatients at all health facilities using standardised criteria for referral. Clinicians then applied criteria for patient investigation. We defined IPD as a compatible illness with isolation of Streptococcus pneumoniae from a normally sterile site (cerebrospinal fluid, blood, or pleural fluid). We compared disease incidence between baseline (May 12, 2008-May 11, 2010) and post-vaccine years (2016-2017), in children aged 2 months to 14 years, adjusting for changes in case ascertainment over time. FINDINGS: We identified 22 728 patients for investigation and detected 342 cases of IPD and 2623 cases of radiological pneumonia. Among children aged 2-59 months, IPD incidence declined from 184 cases per 100 000 person-years to 38 cases per 100 000 person-years, an 80% reduction (95% CI 69-87). Non-pneumococcal bacteraemia incidence did not change significantly over time (incidence rate ratio 0·88; 95% CI, 0·64-1·21). We detected zero cases of vaccine-type IPD in the 2-11 month age group in 2016-17. Incidence of radiological pneumonia decreased by 33% (95% CI 24-40), from 10·5 to 7·0 per 1000 person-years in the 2-59 month age group, while pneumonia hospitalisations declined by 27% (95% CI 22-31). In the 5-14 year age group, IPD incidence declined by 69% (95% CI -28 to 91) and radiological pneumonia by 27% (95% CI -5 to 49). INTERPRETATION: Routine introduction of PCV13 substantially reduced the incidence of childhood IPD and pneumonia in rural Gambia, including elimination of vaccine-type IPD in infants. Other low-income countries can expect substantial impact from the introduction of PCV13 using a schedule of three primary doses. FUNDING: Gavi, The Vaccine Alliance; Bill & Melinda Gates Foundation; UK Medical Research Council; Pfizer Ltd